Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck

Moderna unveiled promising results for its personalized cancer vaccine on Tuesday. The results could spark downtrodden Moderna stock.

Why Merck's $250 Million Investment In Moderna May Have Just Paid Off

mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death compared to KEYTRUDA monotherapy in stage III/IV melanoma patients with high risk of recurrence following complete resection Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial Companies plan to discuss results with regulatory authorities and initiate a Phase 3 study in melanoma in 2023 and rapidly expand to additional tumor types CAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / December 13, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of recurrence-free survival (RFS) versus KEYTRUDA alone for the adjuvant treatment of patients with stage III/IV melanoma following complete resection. Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% (HR=0.56 [95% CI, 0.31-1.08]; one-sided p-value=0.0266) compared with KEYTRUDA alone.

Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial

Axsome Therapeutics

Intuitive Surgical

Here we discuss three medical stocks - AXSM, MRNA and ISRG - that have the potential to create wealth for investors over the coming years.

3 Medical Stocks With Solid Growth Drivers to Keep Track Of

Pfizer

Pfizer VS Moderna Third Quarter Earnings And Revenue

PFIZER VS MODERNA; Which Pharmaceutical Is A Better Stock To Buy Now?

These stocks should help your portfolio shine now and well into the future.

3 Surefire Stocks to End 2022 on a Good Note

BioNTech SE

Amid a rise in seasonal respiratory illnesses in younger children across the country, the FDA broadens the label of authorized bivalent Omicron BA.4/BA.5-adapted vaccines to include children as young as six months.

FDA Approves Pfizer, Moderna's Omicron COVID Jabs in Younger Kids

mRNA-1273.222 Targets the BA.4/BA.5 Strains of Omicron Variant Authorization Is Based Upon Clinical and Pre-Clinical Data for Moderna's Bivalent Vaccines CAMBRIDGE, MA / ACCESSWIRE / December 8, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, in children 6 months through 5 years of age. The authorization is based on a 10 μg booster dose following a completed primary series of Moderna's original vaccine.

Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age

These Top Stocks Are Rebounding: Should You Buy Before 2023?

Current Chief Digital Officer, Marcello Damiani, to retire in March CAMBRIDGE, MA / ACCESSWIRE / December 7, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the appointment of Brad Miller as Chief Information Officer effective January 3. Mr. Miller will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane Bancel.

Brad Miller Joins Moderna as Chief Information Officer

Is Moderna stock a buy after unveiling new test results for its omicron-blocking booster shot? Is MRNA stock a buy right now?

Moderna Stock Is Yo-Yoing On New Omicron Booster Data — Is It A Buy?

Known for its Covid-19 vaccine, Moderna Inc. ( MRNA , Financial) holds a strong position in both clinical development and commercial manufacturing scale for mRNA vaccines. Currently, the company has 44 potential treatments and vaccines in different stages, including 24 undergoing clinical trials.

Moderna Heads Into 2023 With Several Irons in the Fire

Pfizer asked a federal court in Boston on Monday to dismiss Moderna's lawsuit seeking monetary damages for alleged patent violations related to the Covid vaccine.

Pfizer rejects Moderna claim it copied Covid vaccine, accuses rival of rewriting history

Pfizer Inc (NYSE:PFE) and BioNTech have moved to countersue rival Moderna Therapeutics Inc in a legal battle over the development of each company's respective Covid-19 vaccines.  Moderna sued the duo in August, accusing them of copying technology which it had begun developing in 2010, long before the pandemic, and ultimately sought damages for the breaking of three of its patents.

Pfizer legal woes continue with battle against Moderna

Much of the social and economic post-pandemic recovery is accredited to Covid-19 vaccine makers Pfizer (PFE) and Moderna (MRNA). Investors may be wondering if these stocks will continue to be strong investments going into 2023.

Should Investors Buy Pfizer (PFE) & Moderna (MRNA) Stock for 2023?

Moderna has reached an important turning point.

Moderna Stock: Buy, Sell, or Hold in 2023?

Based on that assumption, this would indicate that the annual demand for COVID vaccines would be around 600 million doses.

Moderna Stock Futures: Is COVID Vaccine Maker Moderna Poised To Pop Or Drop?

CAMBRIDGE, MA / ACCESSWIRE / November 29, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Thursday, Dec. 1st at 9:00 a.m. ET. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com.

Moderna to Present at the Piper Sandler 34th Annual Healthcare Conference

BeiGene

Bio-Rad Laboratories

Catalent

DexCom

Edwards Lifesciences

Gilead Sciences

Seagen

West Pharmaceutical Services

The healthcare sector has gained momentum following the COVID-19 pandemic. Several companies gained early regulatory approval for developing COVID-19 drugs and distributing vaccines.

These Are the Five Best and Worst Performing Healthcare Stocks in October 2022

Carrier Global

Caesars Entertainment

Etsy

Match Group

Otis Worldwide

Stanley Black & Decker

Tesla

Zoetis

Tesla isn't the only stock that's struggling in 2022. Nearly 60 S&P 500 stocks — or about 11% — are having their worst year ever.

11% Of S&P 500 Stocks Suffer Their Worst Year Ever

Moderna faces a major transition in 2023.

The Worst Mistake Moderna Investors Can Make in 2023

Albemarle

Inmode Ltd

Sociedad Quimica Y Minera De Chile

Vista Oil & Gas SAB de CV

Vertex Pharmaceuticals

A stock that scores a perfect 10 should be on every investor's list of stocks to buy. Any company that receives full marks on quality, value, or growth are stocks I'd considering a perfect 10.

7 Stocks on the Perfect 10 List

Applied Materials

Stocks that are killed in a given year often come back to life the following year, especially in January.

Moderna, Applied Materials Are Candidates for a January Rebound

Buckle

Century Communities

Netflix

Pinterest

Starbucks

Williams-Sonoma

My task today is to find seven of the most undervalued long-term stocks to buy now. We need to determine two things before stock selection takes place.

News for Moderna Stock (MRNA)